Search Results - Andreu Fernández‐Codina
- Showing 1 - 4 results of 4
-
1
-
2
-
3
Brentuximab vedotin for skin involvement in refractory diffuse cutaneous systemic sclerosis, an open-label trial by Andreu Fernández‐Codina, Tatiana Nevskaya, Murray Baron, C. Thomas Appleton, Matthew J. Cecchini, Amanda Philip, Maha El-Shimy, Louise Vanderhoek, Iago Pinal‐Fernandez, Janet Pope
Published 2024Artigo -
4
IgG4-Related Disease by Andreu Fernández‐Codina, Fernando Martínez‐Valle, Blanca Pinilla, Cristina López, Ines deTorres, Roser Solans‐Laqué, Guadalupe Fraile-Rodríguez, Arnau Casanovas-Martínez, Miguel López-Dupla, Ángel Robles‐Marhuenda, María Jesús Barragán-González, María C. Cid, Sergio Prieto‐González, Pilar Brito‐Zerón, María Teresa Cruces-Moreno, E. Fonseca-Aizpuru, Manuel López-Torres, Judith Gil, Manuel Jesús Núñez-Fernández, José Pardos‐Gea, Gonzalo Salvador-Cervelló
Published 2015Artigo
Search Tools:
Related Subjects
Internal medicine
Medicine
Clinical trial
Disease
Inoculation
Lymphoma
Pathology
Scleroderma (fungus)
Surgery
Abdomen
Adverse effect
Algorithm
Alternative medicine
Angiotensin Receptor Blockers
Angiotensin-converting enzyme
Astrobiology
Azathioprine
Blood pressure
Bosentan
Brentuximab vedotin
CD30
Chemotherapy
Clinical endpoint
Combination therapy
Computer science
Cyclophosphamide
Endothelin receptor
Fibrosis
Gastroenterology
Idiopathic pulmonary fibrosis